Jason McCarthy, an analyst from Maxim Group, maintained the Buy rating on Achieve Life Sciences. The associated price target remains the same with $10.00.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Jason McCarthy’s rating is based on Achieve Life Sciences’ promising developments and strategic advancements. The company has reported strong safety data from its ORCA-OL study, which supports the regulatory review process for its smoking cessation drug, cytisinicline. This milestone is crucial as it aligns with the company’s targeted PDUFA date in mid-2026, indicating progress towards potential market approval.
Additionally, Achieve Life Sciences has been granted an FDA Commissioner’s National Priority Voucher for cytisinicline in e-cigarette and vaping cessation, which allows for an expedited review process. This could lead to an earlier market entry if the upcoming Phase 3 ORCA-V2 trial yields positive results. The company’s financial position, bolstered by recent financing activities, provides a runway into the second half of 2026, further supporting its strategic initiatives and potential growth.
McCarthy covers the Healthcare sector, focusing on stocks such as SCYNEXIS, Neuphoria Therapeutics, and OS Therapies Incorporated. According to TipRanks, McCarthy has an average return of -14.4% and a 33.20% success rate on recommended stocks.
In another report released today, Lake Street also maintained a Buy rating on the stock with a $11.00 price target.